Clinical trial · Interventional
Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection
Tele-expertise for Glycemic Control Monitoring in Patients With Diabetes Hospitalized for Covid-19 Infection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): inclusion difficulties
Summary
Brief summary (as posted)
Diabetes is a major factor of morbi-mortality in Covid-19 infection. Currently, steroid therapy is required in patients under oxygen therapy. This treatment is associated with hyper glycaemia in patients with diabetes. Recommendations for the management of diabetes during Covid-19 infection is to use insulin treatment. The majority of units involves in the management of patient with Covid19 infection are not the experience in managing intensive insulin therapy and the time to ensure this follow-up. All the data in the literature are in favor of a positive impact of telemedicine on the metabolic control of diabetic patients. However, the routine use of telemedicine and more particularly tele-expertise within hospital units is very underdeveloped in France. The epidemic of Covid-19 represents a unique situation where the health authorities recommend to physicians to use telemedicine to ensure the follow-up and optimal management of patients. The aim of this study was to compare the metabolic control of diabetic patients infected with Covid-19 followed in tele-expertise to a group of diabetic patients infected with Covid-19 managed in standard conditions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diabetic Patient (Type 1,2, MODY, Secondary) or With Corticosteroid-induced Diabetes Following Initiation of Corticosteroid Treatment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Continuous blind glucose measurement device (Free style Pro) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Tele-expertise
- description
- Basal-bolus insulin treatment with adaptation of insulin doses according to continuous glucose measurement
- type
- EXPERIMENTAL
- label
- Standard
- description
- Standard treatment and adaptation of insulin doses according to the usual management of the unit
- interventionNames
- Device: Continuous blind glucose measurement device (Free style Pro)
Primary outcomes (1)
- measure
- Percentage of time spent in the range 70-180 mg / dl (TIR)
- timeFrame
- At the end of hospitalization (maximum day 14)
- description
- measured every day in the group followed by tele-expertise compared with group under standard care (comparison of the daily evolution of the TIR in both groups).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient adult hospitalized for Covid-19 infection in the Infectious Diseases Department of the University Hospital of Strasbourg (HUS) * Patient requiring steroid treatment * Diabetic patient (type 1,2, MODY, secondary) or with corticosteroid-induced diabetes following initiation of corticosteroid treatment Exclusion Criteria: * Contraindication to the use of the Free-Style Medical Device
References
Publications (0)
Data not yet available